189 related articles for article (PubMed ID: 32397338)
21. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Wu W; Sigmond J; Peters GJ; Borch RF
J Med Chem; 2007 Jul; 50(15):3743-6. PubMed ID: 17602464
[TBL] [Abstract][Full Text] [Related]
22. Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma.
Du L; Zhang B; Lei Y; Wang S; Jin Y
Biomed Pharmacother; 2016 Apr; 79():208-14. PubMed ID: 27044830
[TBL] [Abstract][Full Text] [Related]
23. Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer.
Kristjansen PE; Brown TJ; Shipley LA; Jain RK
Clin Cancer Res; 1996 Feb; 2(2):359-67. PubMed ID: 9816179
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
van Moorsel CJ; Bergman AM; Veerman G; Voorn DA; Ruiz van Haperen VW; Kroep JR; Pinedo HM; Peters GJ
Biochim Biophys Acta; 2000 Mar; 1474(1):5-12. PubMed ID: 10699484
[TBL] [Abstract][Full Text] [Related]
25. [Pharmacokinetic studies of dFdC (2',2'-difluorodeoxycytidine), ara-C and BH-AC (N4-behenoyl ara-C) in experimental animals].
Okamoto M; Fujita H
Gan To Kagaku Ryoho; 1992 Apr; 19(4):439-44. PubMed ID: 1558392
[TBL] [Abstract][Full Text] [Related]
26. The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Lech-Maranda E; Korycka A; Robak T
Haematologica; 2000 Jun; 85(6):588-94. PubMed ID: 10870114
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Zhao C; Xue X; Li G; Sun C; Sun C; Qu X; Li W
Chem Biol Drug Des; 2012 Sep; 80(3):479-88. PubMed ID: 22642666
[TBL] [Abstract][Full Text] [Related]
28. Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Ruiz van Haperen VW; Veerman G; Boven E; Noordhuis P; Vermorken JB; Peters GJ
Biochem Pharmacol; 1994 Oct; 48(7):1327-39. PubMed ID: 7945430
[TBL] [Abstract][Full Text] [Related]
29. Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts.
Kristjansen PE; Quistorff B; Spang-Thomsen M; Hansen HH
Ann Oncol; 1993 Feb; 4(2):157-60. PubMed ID: 8383519
[TBL] [Abstract][Full Text] [Related]
30. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Hodge LS; Taub ME; Tracy TS
Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
[TBL] [Abstract][Full Text] [Related]
31. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
[TBL] [Abstract][Full Text] [Related]
32. Cellular pharmacology of gemcitabine.
Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic and antitumor effects of a protein kinase C beta inhibitor in human hepatocellular and gastric cancer xenografts.
Teicher BA; Menon K; Alvarez E; Liu P; Shih C; Faul MM
In Vivo; 2001; 15(3):185-93. PubMed ID: 11491013
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2',2'-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine.
Di Stefano G; Busi C; Mattioli A; Derenzini M; Trerè D; Fiume L
Biochem Pharmacol; 1999 Apr; 57(7):793-9. PubMed ID: 10075085
[TBL] [Abstract][Full Text] [Related]
35. Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
Reddy LH; Khoury H; Paci A; Deroussent A; Ferreira H; Dubernet C; Declèves X; Besnard M; Chacun H; Lepêtre-Mouelhi S; Desmaële D; Rousseau B; Laugier C; Cintrat JC; Vassal G; Couvreur P
Drug Metab Dispos; 2008 Aug; 36(8):1570-7. PubMed ID: 18474674
[TBL] [Abstract][Full Text] [Related]
36. Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Bader Y; Hartmann J; Horvath Z; Saiko P; Grusch M; Madlener S; Maier S; Oehler L; Fritzer-Szekeres M; Heller N; Alken RG; Krupitza G; Szekeres T
Cancer Lett; 2008 Feb; 259(2):231-9. PubMed ID: 18023527
[TBL] [Abstract][Full Text] [Related]
37. Encapsulated microRNA by gemcitabine prodrug for cancer treatment.
Zhang HT; Sun J; Yan Y; Cui SH; Wang H; Wang CH; Qiu C; Chen X; Ding JS; Qian HG; Wang JC; Zhang Q
J Control Release; 2019 Dec; 316():317-330. PubMed ID: 31733293
[TBL] [Abstract][Full Text] [Related]
38. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Abbruzzese JL; Grunewald R; Weeks EA; Gravel D; Adams T; Nowak B; Mineishi S; Tarassoff P; Satterlee W; Raber MN
J Clin Oncol; 1991 Mar; 9(3):491-8. PubMed ID: 1999720
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.
Johnson AJ; Brown MN; Black ME
Biochem Biophys Res Commun; 2011 Dec; 416(1-2):199-204. PubMed ID: 22093835
[TBL] [Abstract][Full Text] [Related]
40. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
